Email: cspc@cspc.cn

Contact Us

CSPC Pharmaceutical Group Co., Ltd.

News

News

Home > Media > News > FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (多恩達®) (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASO

FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (多恩達®) (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASO

March 11, 2023

Previous: NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION

Next: NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA

Phone:

+86 311 8703 7015

Email:

Legal terms Privacy protection

Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |